VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2015 | Importance of Bcl-2-targeted therapies

At the American Society of Hematology (ASH) 2015 Annual Meeting, John Gribben, MD, DSc and Stephan Stilgenbauer, MD discuss the importance of Bcl-2-targeted therapies. They discuss recent successes of Bcl-2 targeting drugs, such as venetoclax (ABT-196) in the field of chronic lymphocytic leukemia.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter